KPTI — Karyopharm Therapeutics Share News
0.000.00%
Last trade - 00:00- $11.74m
- $268.91m
- $146.07m
Brief: Karyopharm Reports Prelim Unaudited 2023 Revenue And 2024 Objectives
Brief: Karyopharm Announces New Preliminary Data In Overall Survival In Selinexor-Treated Patients With Advanced Or Recurrent TP53 Wild-Type Endometrial Cancer
Karyopharm Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Karyopharm Therapeutics Q3 Net Income USD -34.506 Million
Karyopharm Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SeaStar, SJW Group, Pinterest
U.S. STOCKS ON THE MOVE-Crypto, Miromatrix Medical, US banks
U.S. STOCKS ON THE MOVE-JinkoSolar, Reviva, MeiraGTx
Karyopharm rises on Bristol Myers collaboration for blood cancer therapy
Brief: Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb
Brief: Karyopharm Therapeutics Board Increased Size Of Board To Nine Members
Brief: Karyopharm Therapeutics Q2 Net Income USD -32.63 Million
Karyopharm Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Karyopharm Receives FDA Fast Track Designation For Selinexor For The Treatment Of Myelofibrosis
Karyopharm rises on FDA's 'fast track' tag for rare blood cancer treatment
Karyopharm Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Karyopharm Therapeutics Q1 product revenue USD 28.288 million
Brief: Karyopharm Reports First Quarter 2023 Financial Results
Karyopharm Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview